ADPT — Adaptive Biotechnologies Balance Sheet
0.000.00%
Last trade - 00:00
- $685.75m
- $525.77m
- $170.28m
- 42
- 18
- 77
- 43
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 577 | 688 | 353 | 498 | 346 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 12.7 | 10 | 17.4 | 40.1 | 38 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 613 | 727 | 403 | 562 | 410 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 60.4 | 139 | 173 | 164 | 120 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 912 | 1,116 | 923 | 857 | 661 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 78.3 | 105 | 114 | 110 | 88 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 341 | 373 | 319 | 392 | 353 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 571 | 743 | 604 | 464 | 308 |
Total Liabilities & Shareholders' Equity | 912 | 1,116 | 923 | 857 | 661 |
Total Common Shares Outstanding |